close
close

AstraZeneca's experimental drug disappoints in breast cancer survival study | Company news

Representative image: The drug previously achieved the main goals of progression-free survival in a study on late-stage breast cancer. (Photo: Shutterstock)

2 minutes reading time Last updated: September 23, 2024 | 1:10 p.m. IS

AstraZeneca announced on Monday that its experimental precision medicine, developed jointly with Japanese company Daiichi Sankyo, did not significantly improve the overall survival rate of patients with a certain type of breast cancer in a late-stage study.

The overall survival or OS rates in the Phase III TROPION-Breast01 study with datopotamab deruxtecan (Dato-DXd) did not reach statistical significance compared with chemotherapy, AstraZeneca said.

This follows similar disappointing results from key lung cancer trials published earlier this month. AstraZeneca shares fell following the trial setback, as investors and analysts predicted the drug could potentially become the company's next top-selling drug.

Dato-DXd belongs to a class of drugs known as antibody-drug conjugates (ADCs), which consist of tumor-seeking monoclonal antibodies combined with a cell-killing chemotherapy effect.

“We will continue discussions with regulators and apply the lessons learned from these results to our clinical development program for datopotamab deruxtecan in breast cancer,” said Susan Galbraith, executive vice president of oncology research and development at AstraZeneca.

The drug previously met its primary goals of progression-free survival in a late-stage breast cancer study.

“We remain committed to making datopotamab deruxtecan another potential option for patients who may benefit from it,” said Ken Takeshita, global head of research and development at Daiichi Sankyo.

(Only the headline and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First published: September 23, 2024 | 1:10 p.m. IS

You may also like...